Glioblastoma (GBM), or grade IV astrocytoma, is a malignant brain cancer that contains subpopulations of proliferative and invasive cells that coordinately drive primary tumor growth, progression, and recurrence after therapy. Here, we have analyzed functions for megalencephalic leukoencephalopathy with subcortical cysts 1 (Mlc1), an eight-transmembrane protein normally expressed in perivascular brain astrocyte end feet that is essential for neurovascular development and physiology, in the pathogenesis of GBM. We show that Mlc1 is expressed in human stem-like GBM cells (GSCs) and is linked to the development of primary and recurrent GBM. Genetically inhibiting MLC1 in GSCs using RNAi-mediated gene silencing results in diminished growth and invasion in vitro as well as impaired tumor initiation and progression in vivo. Biochemical assays identify the receptor tyrosine kinase Axl and its intracellular signaling effectors as important for MLC1 control of GSC invasive growth. Collectively, these data reveal key functions for MLC1 in promoting GSC growth and invasion, and suggest that targeting the Mlc1 protein or its associated signaling effectors may be a useful therapy for blocking tumor progression in patients with primary or recurrent GBM.
Subscribe to Journal
Get full journal access for 1 year
only $9.98 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Wen PY, Weller M, Lee EQ, Alexander BA, Barnholtz-Sloan JS, Barthel FP. et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22:1073–113.
Muir M, Gopakumar S, Traylor J, Lee S, Rao G. Glioblastoma multiforme: novel therapeutic targets. Expert Opin Ther Targets. 2020;24:605–14.
Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin(R)) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.
Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev. 2015;29:1203–17.
Jhaveri N, Chen TC, Hofman FM. Tumor vasculature and glioma stem cells: contributions to glioma progression. Cancer Lett. 2016;380:545–51.
van der Knaap MS, Boor I, Estevez R. Megalencephalic leukoencephalopathy with subcortical cysts: chronic white matter oedema due to a defect in brain ion and water homoeostasis. Lancet Neurol. 2012;11:973–85.
Lopez-Hernandez T, Sirisi S, Capdevila-Nortes X, Montolio M, Fernandez-Duenas V, Scheper GC, et al. Molecular mechanisms of MLC1 and GLIALCAM mutations in megalencephalic leukoencephalopathy with subcortical cysts. Hum Mol Genet. 2011;20:3266–77.
Boor I, Nagtegaal M, Kamphorst W, van der Valk P, Pronk JC, van Horssen J, et al. MLC1 is associated with the dystrophin-glycoprotein complex at astrocytic endfeet. Acta Neuropathol. 2007;114:403–10.
Boor PK, de Groot K, Waisfisz Q, Kamphorst W, Oudejans CB, Powers JM, et al. MLC1: a novel protein in distal astroglial processes. J Neuropathol Exp Neurol. 2005;64:412–9.
Lanciotti A, Brignone MS, Molinari P, Visentin S, De Nuccio C, Macchia G, et al. Megalencephalic leukoencephalopathy with subcortical cysts protein 1 functionally cooperates with the TRPV4 cation channel to activate the response of astrocytes to osmotic stress: dysregulation by pathological mutations. Hum Mol Genet. 2012;21:2166–80.
Jeworutzki E, Lopez-Hernandez T, Capdevila-Nortes X, Sirisi S, Bengtsson L, Montolio M, et al. GlialCAM, a protein defective in a leukodystrophy, serves as a ClC-2 Cl(-) channel auxiliary subunit. Neuron. 2012;73:951–61.
Lopez-Hernandez T, Ridder MC, Montolio M, Capdevila-Nortes X, Polder E, Sirisi S, et al. Mutant GlialCAM causes megalencephalic leukoencephalopathy with subcortical cysts, benign familial macrocephaly, and macrocephaly with retardation and autism. Am J Hum Genet. 2011;88:422–32.
Ambrosini E, Serafini B, Lanciotti A, Tosini F, Scialpi F, Psaila R, et al. Biochemical characterization of MLC1 protein in astrocytes and its association with the dystrophin-glycoprotein complex. Mol Cell Neurosci. 2008;37:480–93.
Capdevila-Nortes X, Jeworutzki E, Elorza-Vidal X, Barrallo-Gimeno A, Pusch M, Estevez R. Structural determinants of interaction, trafficking and function in the ClC-2/MLC1 subunit GlialCAM involved in leukodystrophy. J Physiol. 2015;593:4165–80.
Gilbert A, Vidal XE, Estevez R, Cohen-Salmon M, Boulay AC. Postnatal development of the astrocyte perivascular MLC1/GlialCAM complex defines a temporal window for the gliovascular unit maturation. Brain Struct Funct. 2019;224:1267–78.
Balasubramaniyan V, Vaillant B, Wang S, Gumin J, Butalid ME, Sai K, et al. Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting. Oncotarget. 2015;6:31007–17.
Minata M, Audia A, Shi J, Lu S, Bernstock J, Pavlyukov MS, et al. Phenotypic plasticity of invasive edge glioma stem-like cells in response to ionizing radiation. Cell Rep. 2019;26:1893–905.
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110.
Amiry-Moghaddam M. AQP4 and the fate of gliomas. Cancer Res. 2019;79:2810–1.
Guerrero PA, Tchaicha JH, Chen Z, Morales JE, McCarty N, Wang Q, et al. Glioblastoma stem cells exploit the alphavbeta8 integrin-TGFbeta1 signaling axis to drive tumor initiation and progression. Oncogene. 2017;36:6568–80.
Reyes SB, Narayanan AS, Lee HS, Tchaicha JH, Aldape KD, Lang FF, et al. alphavbeta8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion. Mol Biol Cell. 2013;24:474–82.
Chen Z, Morales JE, Guerrero PA, Sun H, McCarty JH. PTPN12/PTP-PEST regulates phosphorylation-dependent ubiquitination and stability of focal adhesion substrates in invasive glioblastoma cells. Cancer Res. 2018;78:3809–22.
Dundar B, Markwell SM, Sharma NV, Olson CL, Mukherjee S, Brat DJ. Methods for in vitro modeling of glioma invasion: choosing tools to meet the need. Glia. 2020;68:2173–91.
Hoegg-Beiler MB, Sirisi S, Orozco IJ, Ferrer I, Hohensee S, Auberson M, et al. Disrupting MLC1 and GlialCAM and ClC-2 interactions in leukodystrophy entails glial chloride channel dysfunction. Nat Commun. 2014;5:3475.
Hwang J, Vu HM, Kim MS, Lim HH. Plasma membrane localization of MLC1 regulates cellular morphology and motility. Mol Brain. 2019;12:116.
Brignone MS, Lanciotti A, Macioce P, Macchia G, Gaetani M, Aloisi F, et al. The beta1 subunit of the Na,K-ATPase pump interacts with megalencephalic leucoencephalopathy with subcortical cysts protein 1 (MLC1) in brain astrocytes: new insights into MLC pathogenesis. Hum Mol Genet. 2011;20:90–103.
Leegwater PA, Boor PK, Yuan BQ, van der Steen J, Visser A, Konst AA, et al. Identification of novel mutations in MLC1 responsible for megalencephalic leukoencephalopathy with subcortical cysts. Hum Genet. 2002;110:279–83.
Leegwater PA, Yuan BQ, van der Steen J, Mulders J, Konst AA, Boor PK, et al. Mutations of MLC1 (KIAA0027), encoding a putative membrane protein, cause megalencephalic leukoencephalopathy with subcortical cysts. Am J Hum Genet. 2001;68:831–8.
van der Knaap MS, Lai V, Kohler W, Salih MA, Fonseca MJ, Benke TA, et al. Megalencephalic leukoencephalopathy with cysts without MLC1 defect. Ann Neurol. 2010;67:834–7.
Nishizuka SS, Mills GB. New era of integrated cancer biomarker discovery using reverse-phase protein arrays. Drug Metab Pharmacokinet. 2016;31:35–45.
Lewis-Tuffin LJ, Feathers R, Hari P, Durand N, Li Z, Rodriguez FJ, et al. Src family kinases differentially influence glioma growth and motility. Mol Oncol. 2015;9:1783–98.
Ma W, Na M, Tang C, Wang H, Lin Z. Overexpression of N-myc downstream-regulated gene 1 inhibits human glioma proliferation and invasion via phosphoinositide 3-kinase/AKT pathways. Mol Med Rep. 2015;12:1050–8.
Hara A, Kanayama T, Noguchi K, Niwa A, Miyai M, Kawaguchi M, et al. Treatment strategies based on histological targets against invasive and resistant glioblastoma. J Oncol. 2019;2019:2964783.
Peglion F, Goehring NW. Switching states: dynamic remodelling of polarity complexes as a toolkit for cell polarization. Curr Opin Cell Biol. 2019;60:121–30.
Onken J, Vajkoczy P, Torka R, Hempt C, Patsouris V, Heppner FL, et al. Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival. Oncotarget. 2017;8:50403–14.
Sadahiro H, Kang KD, Gibson JT, Minata M, Yu H, Shi J, et al. Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastoma. Cancer Res. 2018;78:3002–13.
Antony J, Huang RY. AXL-driven EMT state as a targetable conduit in cancer. Cancer Res. 2017;77:3725–32.
Rao L, Mak VCY, Zhou Y, Zhang D, Li X, Fung CCY, et al. p85beta regulates autophagic degradation of AXL to activate oncogenic signaling. Nat Commun. 2020;11:2291.
Lanciotti A, Brignone MS, Visentin S, De Nuccio C, Catacuzzeno L, Mallozzi C, et al. Megalencephalic leukoencephalopathy with subcortical cysts protein-1 regulates epidermal growth factor receptor signaling in astrocytes. Hum Mol Genet. 2016;25:1543–58.
Leventoux N, Augustus M, Azar S, Riquier S, Villemin JP, Guelfi S, et al. Transformation foci in IDH1-mutated gliomas show STAT3 phosphorylation and downregulate the metabolic enzyme ETNPPL, a negative regulator of glioma growth. Sci Rep. 2020;10:5504.
Antony J, Tan TZ, Kelly Z, Low J, Choolani M, Recchi C, et al. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. Sci Signal. 2016;9:ra97.
Lanciotti A, Brignone MS, Belfiore M, Columba-Cabezas S, Mallozzi C, Vincentini O, et al. Megalencephalic leukoencephalopathy with subcortical cysts disease-linked MLC1 protein favors gap-junction intercellular communication by regulating connexin 43 trafficking in astrocytes. Cells. 2020;9:1425–45.
Brignone MS, Lanciotti A, Camerini S, De Nuccio C, Petrucci TC, Visentin S, et al. MLC1 protein: a likely link between leukodystrophies and brain channelopathies. Front Cell Neurosci. 2015;9:66.
Turner KL, Sontheimer H. Cl- and K+ channels and their role in primary brain tumour biology. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130095.
Gaitan-Penas H, Apaja PM, Arnedo T, Castellanos A, Elorza-Vidal X, Soto D, et al. Leukoencephalopathy-causing CLCN2 mutations are associated with impaired Cl(-) channel function and trafficking. J Physiol. 2017;595:6993–7008.
McCarty JH. alphavbeta8 integrin adhesion and signaling pathways in development, physiology and disease. J Cell Sci. 2020;133:1–10.
Elorza-Vidal X, Xicoy-Espaulella E, Pla-Casillanis A, Alonso-Gardon M, Gaitan-Penas H, Engel-Pizcueta C, et al. Structural basis for the dominant or recessive character of GLIALCAM mutations found in leukodystrophies. Hum Mol Genet. 2020;29:1107–20.
Amiry-Moghaddam M, Ottersen OP. The molecular basis of water transport in the brain. Nat Rev Neurosci. 2003;4:991–1001.
Waite A, Brown SC, Blake DJ. The dystrophin-glycoprotein complex in brain development and disease. Trends Neurosci. 2012;35:487–96.
We thank the various members of the McCarty laboratory for insightful comments on the paper. This work was supported, in part, by grants to JHM from the Cancer Prevention and Research Institute of Texas (RP180220), the National Institutes of Health (R01NS087635, R21NS103841, and P50CA127001), the Brockman Foundation, and the Terry L. Chandler Foundation. The following NCI-funded Cancer Center Support Grant (CCSG) Core Facilities were instrumental in data acquisition: the shRNA and ORFeome Core, the Research Histopathology Facility, the Flow Cytometry and Cellular Imaging Facility, and the Sequencing and Microarray Facility.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lattier, J.M., De, A., Chen, Z. et al. Megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1) promotes glioblastoma cell invasion in the brain microenvironment. Oncogene (2020). https://doi.org/10.1038/s41388-020-01503-9